Researchers in Pakistan wanted to better understand the effects of anthracycline (a chemotherapeutic drug) on the hearts of young children. More information on the details of their study can be found here:

Objectives: To identify anthracycline induced acute (within one month) and early onset chronic progressive (within year) cardiotoxicity in children younger than 16 years of age with childhood malignancies at tertiary care center of Pakistan. Design: Prospective Cohort study. Setting: Aga Khan University, Karachi, Pakistan. Participants: 110 children (aged 1 month to 16 years). Intervention: Anthracycline (Doxorubicin and/or Daunorubicin). Outcome measurements: All children who received anthracycline as chemotherapy and three echocardiographic evaluations (baseline, one month and 1 year) between July 2010 and June 2012 were prospectively analyzed for cardiac dysfunction. Statistical analysis including systolic and diastolic functions at baseline, 1 month and 1 year were made by repeated measures analysis of variance (r-ANOVA). Results: Mean age was 7444 months and 75 (68.2%) were males. Acute lymphoblastic leukemia (ALL) was seen in 70 (64%) patients. Doxorubicin alone was used in 59 (54%) and combination therapy was used in 35(32%). A cumulative dose of anthracycline <300mg>